Email | Cancel Print Preview Print | Feeds

EXECUTION GUIDANCE FOR THIRD ADDITIONAL TEMPORARY SLOWING AND;FUTURE RESUMPTION OF THE ANTHRAX VACCINE IMMUNIZATION PROGRAM (AVIP) 

R 250920Z JUN 01 ZYW
  FM CMC WASHINGTON DC//PL//
  TO MARADMIN
  BT
  UNCLAS  //N01000//
  MARADMIN 308/01
  MSGID/GENADMIN/CMC WASHINGTON DC/PL//
  SUBJ/EXECUTION GUIDANCE FOR THIRD ADDITIONAL TEMPORARY SLOWING AND
  /FUTURE RESUMPTION OF THE ANTHRAX VACCINE IMMUNIZATION PROGRAM (AVIP)//
  REF/A/CMC MSG/DTG 130900Z DEC 00 (NOTAL)//
  NARR/REF A PROVIDED GUIDANCE FOR THE PREVIOUS AVIP SLOWDOWN.//
  POC/PEARSON, B. D. LTCOL/HQMC, PLN/PEARSONBD@HQMC.USMC.MIL
  /DSN 222-4379/TEL:703-692-4379//
  RMKS/1.  DUE TO CONTINUED DELAYS IN THE AVAILABILITY OF THE FOOD AND
  DRUG ADMINISTRATION (FDA) APPROVED ANTHRAX VACCINE, A THIRD SLOWDOWN
  OF THE AVIP IS DIRECTED.  UNTIL FURTHER NOTICE, ONLY DESIGNATED
  SPECIAL MISSION UNITS, MANUFACTURING AND DOD RESEARCH PERSONNEL, AND
  CONGRESSIONALLY-MANDATED ANTHRAX VACCINE RESEARCH PERSONNEL AND
  RESEARCH FACILITIES WILL CONTINUE TO RECEIVE AND BE PERMITTED TO
  ADMINISTER THE ANTHRAX VACCINE.  THIS MEANS THAT EFFECTIVE
  IMMEDIATELY, AND UNTIL FURTHER NOTICE, MARINE CORPS
  OPERATING FORCES ARE NO LONGER AUTHORIZED TO ADMINISTER THE ANTHRAX    
      VACCINE.  THIS IS A TEMPORARY MEASURE AND COMMANDERS SHOULD EXPECT
  THE PROGRAM TO RESUME IN FULL FORCE AS SOON AS A SUFFICIENT SUPPLY
  OF THE FDA APPROVED VACCINE BECOMES AVAILABLE.
  2.   CHANGES TO THIS POLICY WILL BE DIRECTED BY CMC VIA NAVAL
  MESSAGE.
  3.  UNIT COMMANDERS ARE NOT AUTHORIZED TO MAKE LOCAL EXCEPTIONS TO
  THIS POLICY.  DESIGNATED SPECIAL MISSION UNITS (SMU) CANNOT BE FULLY
  DEFINED HERE DUE TO OPERATIONAL SECURITY.  HOWEVER, ALL UNITS THAT
  WILL CONTINUE TO BE IMMUNIZED WITH THE ANTHRAX VACCINE HAVE BEEN
  PREVIOUSLY CONTACTED BY APPROPRIATE AUTHORITY.  ALL OTHER MARINE
  CORPS OPERATING FORCES WILL CEASE ADMINISTERING VACCINE
  IMMEDIATELY.  AVIP AGENCY IS AUTHORIZED TO GRANT REQUESTS FOR
  DEVIATION FROM THIS POLICY.
  4.  THIS TEMPORARY REDUCTION IN ANTHRAX VACCINE ADMINISTRATION WILL
  REMAIN IN EFFECT UNTIL ADDITIONAL FDA-RELEASED VACCINE BECOMES
  AVAILABLE.  DOD WILL ISSUE FURTHER AVIP GUIDANCE AT THAT TIME.
  5.  EDUCATION MATERIALS ARE AVAILABLE ON THE AVIP WEBSITE,
  WWW.ANTHRAX.OSD.MIL, OR BY CALLING TOLL FREE 1-877-GET-VACC    
      (1-877-438-8222).
  6.  THE AVIP REMAINS A KEY PILLAR IN OUR FORCE HEALTH PROTECTION
  STRATEGY.  DURING THIS VACCINE-SHORT PERIOD, OTHER FORCE HEALTH
  PROTECTION MEASURES SUCH AS INTELLIGENCE COLLECTION, PROTECTIVE
  EQUIPMENT, BIOLOGICAL-AGENT DETECTORS AND ANTIBIOTIC TREATMENT WILL
  HELP PROTECT PERSONNEL AT RISK.  DOD IS WORKING TO RESTORE THE
  SUPPLY OF SAFE AND EFFECTIVE ANTHRAX VACCINE FOR THE RESUMPTION OF
  THE FULL SCALE AVIP.
  7.  ADDITIONAL POINTS OF CONTACT:  PREVENTIVE MEDICINE OFFICER CAPT
  SCHOR (USN) 703-614-4478, DSN 224.  MEDICAL LOGISITCS (REQUISITIONS
  & INVENTORIES): CDR M. READING, 703-695-8926, DSN 225.//
  BT